Dotmatics said this week that Grunenthal Group, a German pharmaceutical company, has licensed its software to manage and analyze chemical and biological data in its projects.
Specifically, Grunenthal will use Vortex, an analytics platform that offers tools for creating and manipulating plots, calculating properties as well as profiling compounds; and Browser, which lets users query and visualize their data.
Henning Steinhagen, senior vice president of Grunenthal's global drug discovery arm, said in a statement that his firm selected Dotmatics' products because they provided "optimal support" for querying, reporting, and analyzing drug-related data. Also, Dotmatics' platform "proved to be the most flexible solution for supporting our multidisciplinary project teams," he said.
The financial details of the licensing agreement were not disclosed.
Other recent licensees of Dotmatics' platform for drug discovery purposes include the University of Leeds (BI 2/15/2013); and the Institute of Cancer Research, London (BI 9/21/2012).